Lymphocytes as a living drug for cancer.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Author(s): Rosenberg, Steven A.
  • Source:
    Science. 7/5/2024, Vol. 385 Issue 6704, p25-26. 2p. 1 Color Photograph.
  • Additional Information
    • Subject Terms:
      T cells; BRAF genes; BREAST; INTERLEUKIN-2; MONOCLONAL antibodies; LYMPHOCYTES; ANTINEOPLASTIC agents
    • Abstract:
      The article discusses the FDA's approval of lifileucel, marking the first use of adoptive cell transfer (ACT) immunotherapy for solid cancers. Lifileucel involves isolating, expanding, and reintroducing a patient's own tumor-infiltrating lymphocytes (TILs) to target cancer cells.Topics include the history of TIL-based ACT, its development challenges including regulatory and manufacturing complexities, and future prospects for expanding this therapy to other solid epithelial cancers.